Sign up now for unlimited free access to Reuters.com
HONG KONG, Sept 4 (Reuters) – China’s CanSino Biologics (6185.HK) said on Sunday that its recently developed Covid-19 vaccine had been approved for emergency use, benefiting its business.
An inhaled Cancino-based adenovirus-vectored Covid-19 vaccine has been approved by the U.S. National Drug Administration, the company said in a filing on Sunday.
“If the vaccine is subsequently purchased and used by the relevant government agencies, approval will have a positive impact on the company’s performance,” CanSino said.
Sign up now for unlimited free access to Reuters.com
However, the company warned that it faces stiff competition from other vaccines that have received government approval or are undergoing clinical trials in China.
China has granted emergency use authorization to promote Livzon Pharmaceutical Group’s (000513.SZ) COVID-19 vaccine, one of two new products that have ravaged China for more than a year, Livzon said on Friday.
Cansino also said it is uncertain when its vaccine will be available, as additional regulatory approvals are still required, and sales will depend on the COVID-19 situation at home and abroad and vaccination rates in China.
Recently, the spread of the new coronavirus in China has been expanding. Shenzhen, the southern tech hub, imposed a weekend lockdown on most of the city on Saturday, while the southwestern metropolis of Chengdu locked down 21 million people on Thursday.read more
Mainland China reported 1,848 new coronavirus cases, both symptomatic and asymptomatic, as of Sept. 3, up from 1,988 a day earlier.read more
Sign up now for unlimited free access to Reuters.com
Reporting by Twinny Chiu in Hong Kong and Samuel Shen in Shanghai; Editing by Edmund Klarman
Our Standards: Thomson Reuters Trust Principles.
“创作者。屡获殊荣的问题解决者。音乐布道者。无法治愈的内向。”